Development Portfolio by Therapeutic Area

Listed below are our clinical studies and approved indications for our marketed products in the related therapeutic area as of February 2, 2024. Whether any of the listed compounds ultimately becomes a marketed product depends on the results of clinical studies, the competitive landscape of the potential product's market, reimbursement decisions by payers and the manufacturing processes necessary to produce the potential product on a commercial scale, among other factors. There can be no assurance that we will seek regulatory approval of any of these compounds or that, if such approval is sought, it will be obtained. There is also no assurance that a compound which gets approved will be commercially successful. At this stage of development, we cannot determine all intellectual property issues or all the patent protection that may, or may not, be available for these investigational compounds.

Hematology

Phase I

Investigational Compounds

alnuctamab+mezigdomide
– Relapsed/Refractory Multiple Myeloma

Anti-SIRPα
– Hematologic Malignancies

BCL6 LDD
– Lymphoma

BCMA NKE
– Relapsed/Refractory Multiple Myeloma

BET Inhibitor (BMS-986378)^
– Relapsed/Refractory Non-Hodgkin's Lymphoma

CD33-GSPT1 ADC
– Acute Myeloid Leukemia

CD33 NKE
– Acute Myeloid Leukemia

CK1α Degrader
– Hematologic Malignancies

Dual Targeting BCMAxGPRC5D CAR T
– Relapsed/Refractory Multiple Myeloma

golcadomide^
– 1L Diffuse Large B-cell Lymphoma

GPRC5D CAR T
– Relapsed/Refractory Multiple Myeloma

Phase II

Additional Indications

BREYANZI
– 3L+ Chronic Lymphocytic Leukemia
– Relapsed/Refractory Follicular Lymphoma
– Relapsed/Refractory Marginal Zone Lymphoma
– Relapsed/Refractory Mantle Cell Lymphoma

REBLOZYL✦
– A-Thalassemia

Investigational Compounds

BET Inhibitor (BMS-986158)
-- 1L Myelofibrosis

golcadomide
--Relapsed/Refractory Non-Hodgkin's Lymphoma

Phase III

Additional Indications

ABECMA✦
– Newly Diagnosed Multiple Myeloma with Suboptimal Response post-ASCT

REBLOZYL✦
– 1L NTD MDS Associated Anemia
– 1L TD MF Associated Anemia

Investigational Compounds

alnuctamab
– Relapsed/Refractory Multiple Myeloma

iberdomide
– 2L+ Multiple Myeloma
– Post-Autologous Stem Cell Therapy Maintenance Newly Diagnosed Multiple Myeloma

mezigdomide
– 2L+ Multiple Myeloma Kd
– 2L+ Multiple Myeloma Vd

Approved Indications

ABECMA
– 5L+ Multiple Myeloma
– 4L+ Multiple Myeloma
– 3L+ Multiple Myeloma

BREYANZI
– 2L Large B-cell Lymphoma
– 3L+ Large B-cell Lymphoma

EMPLICITI✦ **+ *POMALYST/IMNOVID***
– Relapsed/Refractory Multiple Myeloma

EMPLICITI✦ **+ *REVLIMID***
– Relapsed/Refractory Multiple Myeloma

IDHIFA
– Relapsed/Refractory Acute Myeloid Leukemia

INREBIC
– Myelofibrosis

ONUREG
– Post-Induction Acute Myeloid Leukemia Maintenance

OPDIVO✦
– Advanced Hodgkin Lymphoma

POMALYST/IMNOVID
– Multiple Myeloma
– Relapsed/Refractory Multiple Myeloma
– AIDS related Kaposi Sarcoma
– HIV-negative Kaposi Sarcoma

REBLOZYL✦
– Transfusion-Dependent Beta-Thalassemia
– MDS Previously treated with ESA
– 1L Transfusion-Dependent MDS-Associated Anemia

REVLIMID
– 1L Multiple Myeloma
– Mantle Cell Lymphoma
– MDS
– Multiple Myeloma
– Previously treated Follicular Lymphoma
– Relapsed/Refractory Adult T-cell Leukemia/Lymphoma

SPRYCEL
– 1L CML
– Pediatric ALL
– Refractory CML

Development Portfolio by Therapeutic Area

Oncology

Phase I

Investigational Compounds

Anti-CCR8^
– Solid Tumors

Anti-ILT4^
– Solid Tumors

AR LDD
– 1L, 2L+ Metastatic Castration-Resistant Prostate Cancer

DGK Inhibitor
– Solid Tumors

Helios CELMoD
– Solid Tumors

JNK Inhibitor
– Solid Tumors

MAGE A4/8 TCER✦#
– Solid Tumors

NME 1
– Prostate Cancer

PRMT5 Inhibitor
– Solid Tumors

SHP2 Inhibitor✦^
– Solid Tumors

TGFβ Inhibitor^
– Solid Tumors

TIGIT Bispecific✦
– Gastric Cancer

Phase II

Additional Indications

AUGTYRO (repotrectinib)
– NTRK Pan Tumor

KRAZATI
– 1L NSCLC
– 3L+ Colorectal cancer

nivolumab + relatlimab
– 1L Stage IV NSCLC
– 1L Hepatocellular Carcinoma

Investigational Compounds

Anti-CTLA-4 NF Probody Therapeutic
– Lung Cancer
– Colorectal Cancer

Anti-Fucosyl GM1^
– Relapsed/Refractory Small Cell Lung Cancer

Anti-IL8^
– Solid Tumors

Anti-NGK2A^
– Non-Small Cell Lung Cancer

BET Inhibitor (BMS-986378)^
– Solid Tumors

farletuzumab-ecteribulin✦
– Ovarian Cancer
– Non-Small Cell Lung Cancer

Phase III

Additional Indications

KRAZATI
– 1L NSCLC
– 2L Colorectal Cancer

OPDIVO✦
– Peri-adjuvant Muscle Invasive Urothelial Carcinoma
– Adjuvant HCC
– Peri-adjuvant NSCLC
– Stage IB-IIIA Adjuvant NSCLC#

OPDIVO✦ + YERVOY✦
– 1L Muscle Invasive Urothelial Carcinoma
– 1L HCC
– 1L+ MSI-High CRC
– Stage III Unresectable NSCLC

OPDUALAG✦
– Adjuvant Melanoma

Investigational Compounds

subcutaneous nivolumab + relatlimab + rHuPH20✦
– 1L Melanoma

subcutaneous nivolumab + rHuPH20 (multi-indications)✦
– 2L RCC

Approved Indications

ABRAXANE
– Breast
– Gastric
– Locally Advanced or Metastatic NSCLC
– Metastatic Breast Cancer
– NSCLC
– Pancreatic
– Unresectable Pancreatic

AUGTYRO (repotrectinib)
– ROS1 NSCLC

KRAZATI
– Advanced NSCLC with $KRAS^{G12C}$ mutation

OPDIVO✦
– 1L Metastatic Melanoma
– 1L Gastric
– Esophageal Squamous Cell Carcinoma
– 1L Esophageal
– Adjuvant Melanoma
– Adjuvant Bladder
– Adjuvant Esophageal/ Gastroesophageal
– Adjuvant Melanoma Stage IIB/C
– Mesothelioma
– Previously treated advanced RCC
– Previously treated Gastric cancer (Japan, China)
– Previously treated Metastatic Head & Neck
– Previously treated Metastatic Melanoma
– Previously treated Metastatic MSI-High CRC
– Previously treated Metastatic Non-squamous NSCLC
– Previously treated Metastatic Squamous NSCLC
– Previously treated Metastatic Urothelial Cancer
– Previously treated Esophageal Cancer
– Neoadjuvant NSCLC

OPDIVO✦ + cabozantinib✦
– Metastatic RCC

OPDIVO✦ + YERVOY✦
– 1L Metastatic Melanoma
– 1L Mesothelioma
– 1L NSCLC
– 1L RCC
– Previously treated Metastatic MSI-High CRC
– Previously treated HCC
– 1L Esophageal
– 1L Gastric

OPDUALAG
– 1L Melanoma

YERVOY✦
– Adjuvant Melanoma
– Metastatic Melanoma

Development Portfolio by Therapeutic Area

Immunology

Phase I

Investigational Compounds

Anti-CD40
– Autoimmune Disease

CD19 NEX T
– Severe Refractory Systemic Lupus Erythematosus

IL2-CD25
– Autoimmune Disease

NME 2
– Autoimmune Disease

PKCθ Inhibitor
– Autoimmune Disease

Phase II

Additional Indications

SOTYKTU
– Alopecia Areata
– Discoid Lupus Erythematosus

Investigational Compounds

afimetoran
– Systemic Lupus Erythematosus

TYK2 Inhibitor (BMS-986322)
– Moderate-to-Severe Psoriasis

Phase III

Additional Indications

SOTYKTU
– Psoriatic Arthritis
– Systemic Lupus Erythematosus
– Sjögren's Syndrome

ZEPOSIA
– Crohn's Disease

Investigational Compounds

cendakimab
– Eosinophilic Esophagitis
– Eosinophilic Gastroenteritis*

LPA1 Antagonist
– Idiopathic Pulmonary Fibrosis
– Progressive Pulmonary Fibrosis

obexelimab #
– IgG4-Related Disease

Approved Indications

ORENCIA
– Active Polyarticular JIA
– Early Rheumatoid Arthritis
– JIA Intravenous
– JIA Subcutaneous
– Psoriatic Arthritis
– RA Auto injector
– RA Intravenous
– RA Subcutaneous
– Acute Graft versus Host Disease

SOTYKTU
– Moderate-to-Severe Psoriasis

ZEPOSIA
– Relapsing Multiple Sclerosis
– Moderate-to-Severe Ulcerative Colitis

Cardiovascular

Phase I

Investigational Compounds

FXIa Inhibitor
– Thrombotic Disorders

Phase II

Additional Indications

CAMZYOS
– Heart Failure with Preserved Ejection Fraction (HFpEF)

Investigational Compounds

danicamtiv
– Genetic Dilated Cardiomyopathy

MYK-224
– Obstructive Hypertrophic Cardiomyopathy
– Heart Failure with Preserved Ejection Fraction (HFpEF)

Phase III

Additional Indications

CAMZYOS
– Non-obstructive Hypertrophic Cardiomyopathy

Investigational Compounds

milvexian✦
– Acute Coronary Syndrome#
– Atrial Fibrillation#
– Secondary Stroke Prevention (SSP)#

Approved Indications

CAMZYOS
– Symptomatic Obstructive Hypertrophic Cardiomyopathy

ELIQUIS✦
– Stroke Prevention in Atrial Fibrillation
– Venous Thromboembolism Prevention
– Orthopedic Surgery
– Venous Thromboembolism Treatment

Neuroscience

Phase I

Investigational Compounds

Anti-MTBR-Tau
– Alzheimer's Disease

CD19 NEX T
– Multiple Sclerosis

eIF2b Activator✦
– Neuroscience

FAAH/MGLL Dual Inhibitor
– Neuroscience

TYK2 Inhibitor (BMS-986465)
– Neuroinflammation Disorders

Note: Above pipeline excludes clinical collaborations

✦ Development Partnerships: *ABECMA*: 2seventy bio; farletuzumab ecteribulin: Eisai; rHuPH20: Halozyme; MAGEA4/8 TCER: Immatics; milvexian: Janssen Pharmaceuticals Inc., a Johnson & Johnson company ; *OPDIVO, YERVOY, OPDUALAG* in Japan: Ono; PKCθ Inhibitor: Exscientia; *REBLOZYL*: Merck; SHP2 Inhibitor: BridgeBio Pharma; TIGIT Bispecific: Agenus; obexelimab: Zenas BioPharma in Japan, South Korea, Taiwan, HK, Singapore, and Australia
^ Trial(s) exploring various combinations
# Partner-run study
* Japan only